Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of RP 5063 in patients with pulmonary arterial hypertension (PAH)

Next Previous
Trial Profile

A phase II trial of RP 5063 in patients with pulmonary arterial hypertension (PAH)

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs RP 5063 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Oct 2017 According to a Reviva Pharmaceuticals media release, this trial is expected to begin in early 2018.
    • 29 May 2017 New trial record
    • 22 May 2017 According to a Reviva Pharmaceuticals media release, the company anticipates to start this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top